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A B S T R A C T
Toll-like receptors are key players in initiation of innate immune response of the host. In addition to innate immunity
they can also induce adaptive immune responses. The concept that inflammation can promote chronic prostatic diseases,
such as benign prostatic hyperplasia or prostate carcinoma is supported by several new findings. Epidemiological data
have correlated prostatitis with an increased risk of prostate cancer, while PCR-based analyses of bacterial colonization
in prostate cancer specimens and normal prostate tissue showed high correlation of bacterial colonization and chronic
inflammation with a diagnosis of prostate carcinoma. Even evidence from genetic studies support the hypothesis that
prostate inflammation may be a cause of prostate cancer. From these points of view identification of factors, such as SNPs
in TLR genes, associated with risk for prostate carcinoma development seems reasonable. Consequently, there are many
investigations showing the connection between SNPs in TLR genes and pronounced susceptibility to different diseases.
In this article we review the key findings about the genetic variability of TLR genes and prostate cancer risk.
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Introduction
The prostate is a composite exocrine gland divided
into four zones: anterior fibromuscular stroma, periph-
eral zone (PZ), central zone, and preprostatic tissue. The
preprostatic tissue is the smallest, but most complex,
prostate zone. Its main component is a cylindrical,
smooth, muscular sphincter. Inside this muscles are tiny
periurethral glands. The group of glandular ducts that
»escape« the limit of the muscular cylinder and develops
beyond it is called the transitional zone (TZ). This zone
accounts for about 5% of the mass of glandular tissue in
the normal prostate and is the most common site of be-
nign prostatic hyperplasia (BPH). The peripheral zone is
the most frequent site of most prostate carcinomas. The
central zone is relatively insensitive to the appearance of
tumors, but they occur there with a frequency of about
8%. Tumors also occur in the TZ, with a frequency of
about 24%1.
Peripheral zone prostate cancer is the third most
common cause of death from cancer in men of all ages. It
is the most common noncutaneous cancer among U.S.
men2. One in six men will be diagnosed with prostate
cancer; one in 30 will die from the disease. It is rare in
men younger than 40. In the USA, 230.110 men per year
will be diagnosed with prostate cancer; that is one man
diagnosed every 3 minutes. Prostate cancer deaths in
USA are estimated at 29.900 per year; that is one death
every 18 minutes. The risk increases with age, but 25% of
diagnoses are made under age 65. Natural history of
prostate cancer is unknown. Prostate cancer treatment
often depends on the stage of the cancer: how fast the
cancer grows and how different it is from surrounding
tissue helps determine the stage. Treatment may include
surgery, radiation therapy, chemotherapy or control of
hormones that affect the cancer.
Indolent tumors are indistinguishable from aggres-
sive tumors that progress to cancer. The established risk
factors are age, family history, race, and chronic inflam-
mation and infection3. However, there is increasing body
of evidence that inherited genetic variant may predispose
to aggressive but not indolent prostate cancer, which,
when combined with already mentioned risk factors, ul-
timately leads to prostate cancer development4.
The prostate cancers are biologically heterogeneous
diseases. Some are very difficult to destroy and often be-
come androgen independent5. An important factor in
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prostate cancer is the invasiveness. Androgen-independ-
ent tumors are more aggressive, more likely to be chemo-
-resistant and have a higher risk of metastasis.
Toll-like Receptors
Toll-like receptors (TLRs) are a group of evolutionary
conserved family of pattern recognition receptors (PPRs)
which recognize molecular motifs of microbial origin,
known as pattern associated molecular patterns
(PAMPs)6,7.
TLRs are type I membrane proteins characterized by
three domains. The first is the ectodomain which is re-
sponsible for ligand binding. The cytoplasmic domain,
known as TIR-domain, is responsible for downstream
signaling. These two domains are connected by the trans-
membrane region. To date 11 TLRs have been identified
in humans. TLR1, 2, 4 and 6 recognize lipids and lipo-
proteins, TLR5 and 11 bind protein ligands and TLR3, 7,
8 and 9, that are located intracellularly and bind nucleic
acids derived from bacteria and viruses8.
After ligation by specific ligands, TLRs initiate innate
immune response through activation of three main tran-
scription factors: interferon-regulatory factor (IRF3, IRF5
and IRF7), NF-kB and AP-19–11. These transcription fac-
tors stimulate the transcription of inflammatory cyto-
kines, chemokines and interferons (IFNs).
Several adaptor proteins are required for signaling af-
ter TLR activation. These include: myeloid differentia-
tion factor 88 (MyD88) (with the exception of TLR3),
MyD88 adaptor-like (Mal), TIR-related adaptor protein
inducing interferon (TRIF) and Trif-related adaptor mol-
ecule (TRAM)12. TLR3 activates TIR domain-containing
adaptor protein inducing interferon-b (TRIF)-dependent
pathway.
In addition to innate immunity they can also induce
adaptive immune responses through the stimulation of
immature dendritic cells (DCs) which can then migrate
from peripheral tissues to lymph nodes where they pro-
vide naive T-cells with signals required for T-cell activa-
tion TLRs are mainly expressed on the cells of lymphoid
tissues, but nonlymphoid tissues also express consider-
able amounts of different TLRs where they play an es-
sential role in recognizing pathogens and mediating in-
flammatory responses13–17.
However, there is accumulating evidence that TLRs
are also expressed on the cells of a variety of human tu-
mors and tumor cell lines18–20. The first evidence for the
presence of functionally active TLRs on human tumor
cells and their role in preneoplastic to neoplastic tissue
progression was observed in gastric cancer21.
Soon after this finding, functionally active TLRs were
found on a variety of different cancer tissues: TLR3, -4
and -9 on prostate cancer cells22,23.
Genetic Polymorphisms
DNA sequence of all human beings is 99.9% identical.
It differs by 0.1%. Does it make a difference? Yes. 0.1%
difference translates into 3 million separate »spelling«
differences in a genome of 3 billion bases. This is called
genetic polymorphism. Genetic polymorphisms are natu-
rally occurring markers that identify regions of the ge-
nome and vary among the individuals – genetic polymor-
phism is any variant gene that occurs with a frequency of
more than 1% in the normal population. There are many
types of DNA polymorphisms, including restriction frag-
ment length polymorphisms (RFLPs), variable number
of tandem repeats (VNTRs), and single nucleotide poly-
morphisms (SNPs). The latter are alterations in DNA in-
volving a single base pair. SNP’s are the most simple
form and most common source of genetic polymorphism
in the human genome and therefore are often used in
population studies in search of the connection between
pathological changes and certain SNP. Their incidence is
1 per 300–600 bp. It is estimated that up to 10 millions
SNPs are probably present in the human genome. There
are several sorts of SNPs: missense, nonsense, silent,
frameshift and splice site. SNPs located in the coding re-
gion can (but may not) influence the amino acid sequence
in the protein. If the SNP is located in the promotor re-
gion of the gene it may influence the level of its ex-
pression24. Now that the human genome is almost en-
tirely sequenced, attention is turning to the evaluation of
variation. It is estimated that ~60,000 SNPs occur within
exons. The consequences of polymorphisms are: changes
in drug metabolism, drug transport, disease susceptibil-
ity, receptor sensitivity, adverse drug reaction and differ-
ent response of patients to certain therapy.
TLRs are principal mediators of rapid microbial rec-
ognition resulting in acute host responses. Therefore it is
reasonable to assume that the genetic polymorphisms of
TLR genes could influence toll-like receptor mediated
anti-pathogen response, as well as their function in tis-
sue regeneration and/or selective anti cancer activity25,26.
Consequently, there are many studies showing the con-
nection between SNPs in TLR genes and pronounced
susceptibility to different diseases27,28. For instance, an
A-G substitution resulting in Asp299Gly change in TLR4,
has a positive correlation with susceptibility to gram neg-
ative bacterial infections and sepsis, atherosclerosis, as-
thma, malaria and Helicobacter pylori induced gastric
cancer29,30. Polymorphic variant in TLR2, which changes
the amino acid sequence (Arg753Gln), has been reported
to alter the susceptibility to the development of staphylo-
coccal infections and tuberculosis. The polymorphism of
nucleotide at the position 392 in TLR5 gene creates arti-
ficial stop codon resulting in increased susceptibility to
infection caused by bacteria Legionella pneumophila25.
Pirie and coworkers have connected polymorphic mark-
ers 2593C/T, 2642C/A and 2690A/G in a TLR3 gene with
increased risk of diabetes Type I development in blacks
from South Africa31, while Ranjith-Kumar and coworkers
noticed possible connection between polymorphic mar-
ker L412F and asthma32.
The importance of TLRs for tumor immunity is evi-
dent in an increasing body of evidence that TLR-variants
are associated with cancer risk. For instance, SNPs in the
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TLR4 and TLR10 genes are connected with the higher
risk of nasopharingeal cancer development33,34, while
896A>G polymorphism in TLR4 gene increases the risk
of gastric carcinoma development33. The possible cause
of some subtypes of lymphoma is connected to the SNPs
in TLR1, -2, -4, -5 and -9 genes35.
Genetic Polymorphisms and Prostate
Cancer
The concept that inflammation can promote chronic
prostatic diseases, such as benign prostatic hyperplasia
or prostate carcinoma, is supported by several new find-
ings. Epidemiological data have correlated prostatitis
with an increased risk of prostate cancer, while PCR-
-based analyses of bacterial colonization in prostate can-
cer specimens and normal prostate tissue showed high
correlation of bacterial colonization and chronic inflam-
mation with a diagnosis of PC36,37. Even evidence from
genetic studies support the hypothesis that prostate in-
flammation may be a cause of prostate cancer. From
these points of view, it is necessary to identify the factors,
such as SNPs in TLR genes, which are associated with
risk for prostate carcinoma development is needed.
The first observation of the connection between TLR
genes polymorphisms and susceptibility to prostate can-
cer development came in 200438. The authors performed
a systematic genetic analysis of TLR4 sequence variants
by evaluating eight SNPs that span the entire gene, in a
large population-based prostate cancer (1383 newly diag-
nosed prostate cancer patients) case-control (780 con-
trols) study in Sweden. They found an association be-
tween a sequence variant 11381 G/C in the 3’-untrans-
lated region and prostate cancer risk. Carriers of the ge-
notype variant CG or CC had increased risk of prostate
cancer and earlier onset of the disease (before the age of
65 years) when compared with the controls (wild type ge-
notype GG), as well as. Obviously, sequence variants in
the genes that regulate inflammation may modify indi-
vidual susceptibility to prostate cancer. However, in one
latter, more extended study considering both, the num-
ber of tested individuals as well as number of SNP geno-
typed, SNP 11381G/C was not associated with risk of
prostate cancer development. On the other hand, 8 SNP
variants showed an inverse association with prostate
cancer risk39. However, the association between six com-
mon haplotypes and prostate cancer was observed. The
authors also found that the age modified the association
between TLR4 SNPs and prostate cancer. Among men
aged <65, carriers of certain SNPs had a lower risk of
prostate cancer, indicating that TLR4 polymorphism had
a greater influence among younger men. Similarly,
Cheng et al. have shown that inherited variation in
TLR4, 5’-UTR polymorphism – rs 10759932, but not the
polymorphism 11381G/C, influences prostate cancer
risk40.
Apart from TLR4, SNP sequence variants in the
TLR6-TLR1-TLR10 gene cluster have also been shown to
be connected with prostate cancer risk in Swedish popu-
lation. The authors found that eight SNPs and six
haplotypes in the same gene cluster were associated with
prostate cancer risk40,41. Contrary to this are the results
of Chen et al.42. The authors assessed if genetic polymor-
phisms of TLR6-TLR1-TLR10 gene cluster were associ-
ated with the risk of prostate cancer in US population.
However, neither individual SNPs nor common hap-
lotypes in this gene region were associated with altered
risk of prostate cancer. Thus, these two studies yielded
inconsistent results. In an attempt to clarify whether
these opposite results reflect differences in ethnic homo-
geneity of tested populations (Swedish – more homoge-
nous than US population) Stevens et al. performed more
expanded study in which they enrolled 1414 men diag-
nosed with prostate cancer and the same number of
healthy matched control men. They genotyped 28 SNPs
in the region of chromosome 4p14 that include the genes
for TLR6-TLR1-TLR10. Two SNPs in TLR10 and four
SNPs in TLR1 were associated with reduced risk of pros-
tate cancer. Haplotype analysis and linkage disequilib-
rium findings revealed their mutual dependency which
shows that they represent a single association with re-
duced prostate cancer risk43.
Of special interest is searching for the variants of the
broader spectrum of genes involved in inflammation, in-
cluding those connected to the Toll-like receptor signal-
ing pathways. Namely, detection of such variants in dif-
ferent groups of patients, including cancer patients,
might help to estimate the predisposition for the develop-
ment of different diseases and for the estimation of the
patient’s response to immunotherapy. One such study
was done by Sun et al.44. Interleukin – receptor-associ-
ated kinases (IRAK) 1 and 4 are critical components in
the TLR signaling pathway. In a large case-control study
the authors tested whether SNP sequence variants in
IRAK1 and -4 genes are associated with prostate cancer
risk, and whether there is a correlation between IRAK
and TLR1-6-10 gene sequence variants. IRAK SNP
polymorphisms did not correlate with prostate cancer
risk. However, one SNP in IRAK4 when combined with
the high risk genotype of TLR1-6-10, conferred a signifi-
cant excess risk of prostate cancer, suggesting synergistic
effect between these two gene variants. Additionally, the
potential role of common SNPs of a gene cluster TLR4,
TLR2, PTGS2 and 5-Lo, involved in innate and inflam-
matory response was investigated, in prostate cancer
cases, age-matched controls and centenarians from Sic-
ily. Statistical analysis evidenced a significant association
of certain SNPs in pro-inflammatory genes with an in-
creased risk of prostate cancer45.
It is also important to mention the enormous work
done by Stark et al.46. The authors quantified the effects
of 99 different SNPs and haplotypes in 20 genes involved
in TLR signaling on specific prostate carcinoma mortal-
ity. This research was conducted on 1.252 prostate carci-
noma patients. Ten TLR genes (TLR1, -2, -3, -4, -5, -6, -7,
-8, -9 and -10) and 10 genes involved in TLR signal
transduction or in final TLR physiological impact (COX-2,
IL-1RN, IL-6, IL-10, IRAK1, IRAK4, MIC-1, MyD88,
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TIRAP, TNF-a) were analyzed. However, prostate carci-
noma mortality was not significantly associated neither
with haplotypes nor with specific SNP’s.
The inconsistent results regarding both, genetic vari-
ants in Toll-like receptor genes as well as in the genes in-
cluded in Toll-like receptor signaling pathway, clearly
support the need for further investigations. Prostate
cancer is a biologically heterogeneous disease, without
reliable prognostic factors, such as relationship between
genetic and phenotypic profile. Therefore it is for the
time being impossible to predict tumor behavior in a
sense of their progression and spread.
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POLIMORFIZMI GENA ZA TOLL-LIKE RECEPTORE – UTJECAJ NA RAZVITAK KARCINOMA
PROSTATE
S A @ E T A K
Toll-like receptori su klju~ni za pokretanje priro|enog imunolo{kog odgovora doma}ina. Pokre}u i ste~eni imunolo-
{ki odgovor. Ideja da upala mo`e uzrokovati kroni~ne bolesti prostate, kao {to je dobro}udna hiperplazija, ali i razvitak
karcinoma, ima sve vi{e potvrda. Tako su npr. rezultati epidemiolo{kih studija pokazali povezanost prostatitisa i po-
ve}anog rizika razvitka carcinoma prostate; genske su analize pokazale povezanost kolonizacije bakterija u uzorcima
normalnog tkiva prostate i tkiva karcinoma prostate i kroni~ne upale. I analize gena ~iji su proteinski produkti uklju-
~eni u pokretanje i provo|enje imunolo{kog odgovora potkrepljuju hipotezu da i kroni~na upala, izme|u ostalog, do-
prinosi razvitku karcinoma prostate. S obzirom na ove ~injenice pronalazak ~imbenik (kao {to su npr. SNP-ovi u genima
za TLR) povezanih s rizikom razvitka karcinoma prostate se ~ini opravdanom. Shodno tome ve} postoji niz istra`ivanja
koja pokazuju povezanost izme|u SNP-ova u genima za TLR i pove}ane podlo`nosti razvitka razli~itih bolesti. U ovom
~lanku opisani su klju~ni nalazi o genskoj varijabilnosti gena za TLR i rizika razvitka tumora prostate.
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